论文信息 - Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial - 字舞流文

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman | A. Ribas | P. Scumpia | Douglas B. Johnson | S. Patel | S. Hu-Lieskovan | J. Moon | S. Chandra | F. Collichio | K. Margolin | N. Khushalani | K. Grossmann | B. Chmielowski | A. Vanderwalde | Z. Eroglu | K. Kendra | E. Sharon | Agustin Vega-Crespo | C. Dasanu | Yuanbin Chen | D. Portnoy | T. Truong | A. Victor | L. Kuklinski | A. Ikeguchi | C. Bane | Ivan Perez Garcilazo | Egmidio Medina | Ignacio Baselga-Carretero | Shay Bellasea | Katie M. Campbell | Michael C. Wu | Hu-Lieskovan Siwen | Cynthia R. Gonzalez

[1] Christopher R. Cabanski,et al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses , 2022, Journal for ImmunoTherapy of Cancer.

[2] Vanessa M. Hubbard-Lucey,et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce , 2020, Journal for ImmunoTherapy of Cancer.

[3] D. Pe’er,et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies , 2019, Proceedings of the National Academy of Sciences of the United States of America.

[4] J. Taube,et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.

[6] Dana Pe’er,et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[7] K. Flaherty,et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[8] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[9] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[10] J. Wolchok,et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[11] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[12] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.

[13] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[14] R. Emerson,et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes , 2014, Oncoimmunology.

[15] Antoni Ribas,et al. Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[16] A. Ribas,et al. Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab , 2010, Journal of Nuclear Medicine.